Kalamazoo, Mich.-based Stryker Corp. just scored a win after the FDA gave the green light for marketing two Trevo clot retrieval devices as first-line treatments to reduce disability in patients experiencing ischemic stroke. It is the first therapy to receive the front-line designation in this indication in 20 years, the company said.

Washington-based Danaher Corp. (NYSE: DHR) determined that buying molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) will boost its position in the molecular diagnostics space, but Danaher's investors may take more convincing.